GO
Loading...

Biotechnology

More

  • Here's what's pushing biotech lower: Expert     Friday, 11 Apr 2014 | 8:42 AM ET

    I think a lot of it had to do with pricing concerns over Gilead's Sovaldi, says Jason Kolbert, Maxim Group, sharing his thoughts on the future of the biotech sector and pending IPOs.

  • Studies: Lab-grown nostrils, vaginas working well Friday, 11 Apr 2014 | 4:25 AM ET

    LONDON— Two new studies describe the latest achievements in growing body parts in a lab and transplanting them into people, this time with nostrils and vaginas. Martin Birchall, of The Ear Institute at University College London, who co-authored an accompanying commentary.

  • *Biotech indexes have worst day since August 2011. *Bed, Bath& Beyond slumps after earnings. NEW YORK, April 10- U.S. stocks sank on Thursday, with the S&P 500 turning negative for the year and the Nasdaq falling its most in a day since June 2012 as investors again sold high-flying names in the technology and biotech sectors and sought shelter in defensive names.

  • Pfizer CEO worries about ACA coverage     Thursday, 10 Apr 2014 | 11:43 AM ET

    Ian Read, Pfizer CEO, discusses the pricing and affordability of drugs in the U.S. Read also weighs in on insurance coverage under the Affordable Care Act.

  • CNBC's Jim Cramer speaks with Robert Hugin, Celgene chairman & CEO, about America's need to build a stronger and more sustainable ecosystem of innovation to continue as the world leader in biomedical innovation.

  • Eli Lilly CEO: We keep investing in R&D     Thursday, 10 Apr 2014 | 6:51 AM ET

    John Lechleiter, Chairman, President & CEO of Eli Lilly, discusses the company's growth plans as products come off patent and consumers move to generic drugs.

  • The biotech parade     Wednesday, 9 Apr 2014 | 12:27 PM ET

    CNBC's Meg Tirrell provides insight on the increase in biotech IPOs, and what to expect from both Cerulean Pharma & Adamas Pharmaceuticals ahead of their IPO pricing Wednesday night.

  • There’s still value in biotech stocks: Citi pro Monday, 7 Apr 2014 | 6:23 PM ET

    Despite the recent meltdown in biotech, there are still areas of opportunity within the sector, Citi's Yaron Werber says.

  • Diversifying your pharma portfolio     Monday, 7 Apr 2014 | 1:07 PM ET

    Mallinckrodt is buying drug maker Questcor for $5.6 billion. Barbara Ryan, FTI Consulting managing director, discusses consolidation in pharmaceuticals and shares what stocks she likes in the space.

  • CNBC's Seema Mody and Dominic Chu look at what's behind today's massive market sell off including biotechs and online retailers.

  • Heather Bresch Mylan CEO, discusses the concern over capping drug prices and the impact of Obamacare on rising drug costs.

  • Why investors should be exposed to biotech     Monday, 31 Mar 2014 | 5:30 AM ET

    Jason Kolbert, head of health care research at Maxim Group, says that last week's biotech sell-off was not justified as the sector is going through a "paradigm shift" which should results in higher valuations.

  • Max Herrmann, partner and healthcare research analyst at Oriel Securities, said biotech stocks have gone through a correction after a "phenomenal" rally.

  • Why drug treatment prices vary     Wednesday, 26 Mar 2014 | 1:08 PM ET

    The U.S. government is prohibited by law from negotiating drug prices, reports CNBC's Sheila Dharmarajan.

  • Reasons to stick with biotech     Tuesday, 25 Mar 2014 | 3:37 PM ET

    CNBC's Sheila Dharmarajan discusses the beat down biotech stocks have recently taken and gives 3 reasons why investors should stick with the sector.

  • Reasons to stick with biotech     Tuesday, 25 Mar 2014 | 1:07 PM ET

    CNBC's Sheila Dharmarajan reports why analysts think investors should stick with the biotech sector.

  • Gilead's next move     Tuesday, 25 Mar 2014 | 12:13 PM ET

    Gilead received a letter from U.S. lawmakers questioning the pricing of its hepatitis c drug Solvadi. Mark Schoenebaum, ISI Health Care Research Group senior managing director, provides perspective.

  • Cramer: Need to see IPO competition cease     Tuesday, 25 Mar 2014 | 9:01 AM ET

    CNBC's Jim Cramer shares his thoughts on yesterday's Nasdaq selloff and the slumping biotech sector.

  • Biotech could see more weakness: Pro     Monday, 24 Mar 2014 | 2:03 PM ET

    Barbara Ryan, FTI Consulting, and Matt Maley, MillerTabek and Company, discuss what has propelled the massive sell-off in the biotech sector.

  • Biotech's big drop     Monday, 24 Mar 2014 | 1:01 PM ET

    CNBC's Dominic Chu digs into the battered biotech sector and reveals which stocks are still sliding.

Most Popular Video

Thursday, 17 Apr 2014 | 3:40 PM ET

President Obama speaks about the 8 million Americans who have signed up for the Affordable Care Act through marketplaces.

Thursday, 17 Apr 2014 | 4:00 PM ET

CNBC's Patti Domm discusses the key market movers to watch for next week.

Thursday, 17 Apr 2014 | 2:41 PM ET

Both Monaco and Miami have soaring real estate prices. CNBC's Robert Frank reports the super rich are really transforming Miami.